Why Novo Nordisk Stock Pumped Higher on Thursday
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. That rise easily bettered the 0.4% gain of the S&P 500 index.That news concerned amycretin, an investigational weight-loss drug that would represent a step up from the highly popular Wegovy. Novo Nordisk reported that it is advancing amycretin to a phase 3 study. Image source: Getty Images.Continue reading
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. That rise easily bettered the 0.4% gain of the S&P 500 index.
That news concerned amycretin, an investigational weight-loss drug that would represent a step up from the highly popular Wegovy. Novo Nordisk reported that it is advancing amycretin to a phase 3 study.
Image source: Getty Images.
